Drug Database
ZO

zolpidem tartrate (Stilnox CR / FK199B / Stilnoxium)

✓ Approved

Astellas Pharma · GABRA1 · Small Molecule

What is zolpidem tartrate?

zolpidem tartrate is a small molecule developed by Astellas Pharma. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesStilnox CR, FK199B, Stilnoxium
CompanyAstellas Pharma
Drug ClassSmall Molecule
Molecular TargetGABRA1
RouteOral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

zolpidem tartrate acts on 1 molecular target:

GABRA1gamma-aminobutyric acid type A receptor alpha1 subunit (DEE19, ECA4)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

zolpidem tartrate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Psychiatric disordersInsomnia✓ Approved

Related Research Articles

PubMedCureus2026-08-30

Recurrent Catatonia in the Setting of Urinary Tract Infection and Medical Comorbidity: A Case Report.

Traugott Paula P, Mimbella Rachel R, Irizarry Flores Jessica C JC, Kyomen Helen H HH

Catatonia is a neuropsychiatric syndrome characterized by disturbances in motor activity, affect, and autonomic function. Although often associated with primary mood or psychotic disorders, it can be precipitated or sustained by systemic infections such as urinary tract infection (UTI). We describe a 60-year-old man with recurrent catatonia and diagnoses of schizophrenia, bipolar disorder, and major neurocognitive disorder, whose latest episode of catatonia, described in this case report, was preceded by psychosocial stress and appeared to be exacerbated by polymicrobial UTI, bacteremia, and urosepsis. He had a history of neuroleptic malignant syndrome (NMS) and an inconsistent response to electroconvulsive therapy (ECT), limiting usual first-line treatment options. During this admission, he developed Klebsiella pneumoniae UTI with Staphylococcus simulans bacteremia and later Pseudomonas aeruginosa urosepsis, in the context of mixed central and nephrogenic diabetes insipidus likely related to long-term lithium therapy. The patient's catatonia proved refractory to very high-dose lorazepam but improved with an intensive, multimodal regimen including intravenous (IV) benzodiazepines (diazepam, midazolam), enteral and subsequently oral lorazepam, zolpidem, memantine, and aggressive treatment of infection and electrolyte abnormalities. He ultimately regained baseline function and was discharged on a slow taper of benzodiazepines and zolpidem. This case illustrates the bidirectional relationship between infection, autonomic and immune dysregulation, and catatonia; highlights practical challenges when treatment with benzodiazepines and ECT is constrained by medical comorbidity; and supports considering adjunctive GABAergic and glutamatergic agents in carefully selected cases of refractory catatonia, under close specialist supervision.

PubMedArthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association2026-08-30

Meniscal Repairs Performed With Posterior Cruciate Ligament Reconstruction Are Associated With Lower Failure Rates Than Isolated Repairs.

Varady Nathan H NH, Parise Suhas S, Ranawat Anil S AS, Williams Riley J RJ

To assess the incidence of meniscal repair (MR) failure after posterior cruciate ligament reconstruction (PCLR) + MR compared with MR alone. Patients undergoing isolated PCLR + MR or MR alone were identified from a large insurance database (PearlDiver). A cohort of isolated ACLR + MR was also developed to provide reference data. Demographic, surgical, and comorbidity data were collected and controlled for. The primary outcome was ipsilateral repair failure defined as revision meniscal surgery at 2 years. Secondary outcomes included ipsilateral revision or conversion arthroplasty (RoA). Time-to-event analyses were used to compare outcomes between groups. There were 21,358 patients (0.9% PCLR + MR, 99.1% MR alone) with a mean follow-up of 3.1 ± 2.1 years. Compared with patients who underwent MR alone, patients who underwent PCLR + MR had significantly lower meniscal failure (unadjusted: 4.1% vs 8.4%, P = .04; adjusted hazard ratio [HR]: 0.41 [0.20-0.82], P = .01) and RoA (unadjusted: 4.1% vs 8.7%, P = .03; adjusted HR: 0.40 [0.20-0.80], P = .01) rates at 2 years. For reference, compared with MR alone, a similar improvement in failure rates was seen with concomitant ACLR + MR (unadjusted: 5.6% vs 8.4%, P < .001; adjusted HR: 0.61 [0.57-0.66], P < .001), whereas there was no difference between PCLR + MR and ACLR + MR (unadjusted: 4.1% vs 5.6%, P = .40; adjusted HR: 0.64 [0.32-1.29], P = .21). MRs performed concomitantly with PCLR were associated with significantly lower failure rates compared with isolated MRs, with an effect size comparable to that of ACLR + MR. Level III, retrospective comparative cohort study.

PubMedNational science review2026-08-30

Tetraboron MR framework with ortho-B-π-B pattern enables high-efficiency yellow narrowband OLEDs.

Zhang Shuqi S, Yang Yongliu Y, Cheng Zhangli Z, Zhang Tongyuan T et al.

Multiple resonance (MR) frameworks with ortho-boron-π-boron (B-π-B) patterns are promising alternatives to those with para-B-π-B ones for realizing bathochromic narrowband emission, but such cases have been rarely reported, and suffer from significant synthetic challenges. Here, a novel tetraboron MR framework ICZ4B incorporating an ortho-B-π-B pattern was constructed by using indolo[2,3-c]carbazole as the central building block. The well-defined borylation active sites facilitate an efficient one-shot quadruple borylation. ICZ4B not only exhibits bright yellow emission with a small full width at half maximum of 24 nm, but also achieves an improved reverse intersystem crossing rate of 4.7 × 104 s-1. The non-sensitized device realizes an outstanding external quantum efficiency of 36.5%, representing one of the highest results at long wavelengths. This study not only presents a feasible pathway for realizing MR frameworks with ortho-B-π-B patterns via delicate selection of key precursors, but also offers insights for optimizing synthetic strategies for complex MR frameworks.

PubMedEuropean heart journal. Cardiovascular Imaging2026-08-30

Platelet activation and thrombosis in microvascular obstruction.

Balmforth Craig C, Giaj Levra Alessandro A, Whittington Beth B, Morgan Aidan A et al.

Microvascular obstruction (MVO) remains a major complication following coronary reperfusion, but its pathogenesis is poorly defined. We evaluated myocardial platelet activation and thrombosis using fluorine-18-labelled GP1 ([18F]GP1) positron emission tomography (PET) in patients with anterior ST-segment elevation myocardial infarction. In a single-centre observational cohort study, 100 patients with acute anterior ST-segment elevation myocardial infarction underwent hybrid cardiac [18F]GP1 PET and magnetic resonance (MR) imaging with gadolinium enhancement and repeat imaging at 3-6 months. Myocardial [18F]GP1 uptake was quantified using target-to-background ratio (TBRmax) and percentage myocardial uptake (burden) and compared with MR measures of infarction, MVO and adverse ventricular remodelling. One hundred patients (60 ± 10 years, 91% male) underwent [18F]GP1 PET/MR imaging at a median of 13 days following index presentation. Increased myocardial [18F]GP1 uptake was observed in 44% of participants (TBRmax 1.89 ± 0.50). All 40 patients with MR-defined MVO demonstrated myocardial [18F]GP1 uptake. Myocardial [18F]GP1 uptake burden correlated with (ρ = 0.84; P < 0.001), and exceeded (by 18%), MR-defined burden of MVO. Myocardial [18F]GP1 uptake was associated with infarct size, lower left ventricular ejection fraction and longer time-to-reperfusion. Angiographic no-reflow was the strongest independent association of MVO (adjusted odds ratio 16.15; P < 0.001). Persistent myocardial [18F]GP1 uptake at follow up (22%, 7/32) was associated with lower left ventricular ejection fraction. Resolution of cardiac MR-defined MVO was observed in 78% of patients at follow-up and was universally concordant with resolution of myocardial [18F]GP1 uptake. MVO following ST-segment elevation myocardial infarction is universally associated with myocardial platelet activation, extending beyond structural abnormalities identified by cardiac MR. These findings are consistent with an important mechanistic contribution of platelet-mediated microvascular thrombosis to no-reflow and MVO, highlighting a potentially targetable biological pathway in a condition for which effective therapies remain elusive.

PubMedClinical, cosmetic and investigational dermatology2026-08-30

Body Mass Index and Facial Aging: Mendelian Randomization and Exploratory Target Prioritization.

Hu Yuan Y, Li Ke-Han KH, He Ming-Jie MJ, Yu Chun-Shui CS et al.

Facial aging reflects genetic, metabolic, and environmental influences. Although obesity has been associated with older perceived facial age, the shared genetic basis and direction of the BMI-facial aging relationship remain uncertain. To evaluate genetic correlations between facial aging and 15 metabolic traits, assess bidirectional associations by Mendelian randomization (MR), and conduct exploratory locus, gene, and compound prioritization. Public genome-wide association study (GWAS) summary statistics were analyzed using linkage disequilibrium score regression (LDSC) and bidirectional MR with inverse-variance weighted (IVW), weighted median, MR-Egger, and MR-PRESSO methods. Because BMI showed the most consistent signal, related loci were evaluated by fine-mapping, colocalization, ANNOVAR, MAGMA, and GCTA-fastBAT. DGIdb screening and molecular docking were used for hypothesis generation. BMI showed the strongest genetic correlation with facial aging (rg = 0.215; FDR-adjusted P = 3.94×10-33). After MR-PRESSO outlier removal, higher genetically predicted BMI was associated with greater odds of appearing older (IVW OR = 1.053, 95% CI 1.044-1.063; P = 1.80×10-28), although heterogeneity remained and reverse-direction estimates were less robust. Of four retained variants, three met the prespecified colocalization threshold. JAZF1, RAD52, and PPARG were prioritized by positional and gene-based analyses. Docking of five natural compounds did not establish target engagement or efficacy. The facial-aging phenotype was perception-based, the GWAS datasets were predominantly of European ancestry and may have partially overlapping samples, and all downstream analyses were computational. Higher BMI may contribute to perceived facial aging, but these findings do not show that BMI reduction or any candidate compound improves facial aging. Metabolic health is the more clinically actionable implication, whereas the prioritized genes and compounds remain exploratory and require functional validation.

PubMedEuropean heart journal2026-08-30

Risk prediction by new adrenomedullin (ADM) system biomarkers: are they any better than mid-regional pro-ADM (MR-proADM) in patients with ACS?

Frydland Martin Steen MS, Møller Jacob Eifer JE, Hassager Christian C

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about zolpidem tartrate